HIV-1 Reverse Transcriptase Still Remains a New Drug Target: Structure, Function, Classical Inhibitors, and New Inhibitors with Innovative Mechanisms of Actions.
about
Focus on Chirality of HIV-1 Non-Nucleoside Reverse Transcriptase InhibitorsComputational drug design strategies applied to the modelling of human immunodeficiency virus-1 reverse transcriptase inhibitorsAPOBEC3 Interference during Replication of Viral GenomesRibonuclease H/DNA Polymerase HIV-1 Reverse Transcriptase Dual Inhibitor: Mechanistic Studies on the Allosteric Mode of Action of Isatin-Based Compound RMNC6Role of N-terminal extension of Bacillus stearothermophilus RNase H2 and C-terminal extension of Thermotoga maritima RNase H2.Biophysical Insights into the Inhibitory Mechanism of Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors.Inhibition of foamy virus reverse transcriptase by human immunodeficiency virus type 1 RNase H inhibitorsVirtual screening of Indonesian herbal database as HIV-1 reverse transcriptase inhibitor.Cytotoxic and HIV-1 enzyme inhibitory activities of Red Sea marine organismsA cell-based strategy to assess intrinsic inhibition efficiencies of HIV-1 reverse transcriptase inhibitors.Silent mutations at codons 65 and 66 in reverse transcriptase alleviate indel formation and restore fitness in subtype B HIV-1 containing D67N and K70R drug resistance mutations.Divalent metal ion-induced folding mechanism of RNase H1 from extreme halophilic archaeon Halobacterium sp. NRC-1.Identification of mechanistically distinct inhibitors of HIV-1 reverse transcriptase through fragment screening.Inhibition of HIV-1 Reverse Transcriptase Dimerization by Small Molecules.Studies on Cycloheptathiophene-3-carboxamide Derivatives as Allosteric HIV-1 Ribonuclease H Inhibitors.NMR characterization of HIV-1 reverse transcriptase binding to various non-nucleoside reverse transcriptase inhibitors with different activities.Human Immunodeficiency Virus (HIV).Chelation Motifs Affecting Metal-dependent Viral Enzymes: N'-acylhydrazone Ligands as Dual Target Inhibitors of HIV-1 Integrase and Reverse Transcriptase Ribonuclease H Domain"Old Dogs with New Tricks": exploiting alternative mechanisms of action and new drug design strategies for clinically validated HIV targets.Identification of highly conserved residues involved in inhibition of HIV-1 RNase H function by Diketo acid derivatives.Application of Site-Specific Spin Labeling for NMR Detecting Inhibitor-Induced Conformational Change of HIV-1 Reverse Transcriptase.A novel mutation, D404N, in the connection subdomain of reverse transcriptase of HIV-1 CRF08_BC subtype confers cross-resistance to NNRTIs.Role of RNase H1 in DNA repair: removal of single ribonucleotide misincorporated into DNA in collaboration with RNase H2.Mechanism of Inhibition of Hsp90 Dimerization by Gyrase B Inhibitor Coumermycin A1 (C-A1) Revealed by Molecular Dynamics Simulations and Thermodynamic Calculations.Single Active Site Mutation Causes Serious Resistance of HIV Reverse Transcriptase to Lamivudine: Insight from Multiple Molecular Dynamics Simulations.[Human immunodeficiency virus: position of Blood Working Group of the Federal Ministry of Health].Double Variational Binding--(SMILES) Conformational Analysis by Docking Mechanisms for Anti-HIV Pyrimidine Ligands.Biological Activities of Aerial Parts Extracts of Euphorbia characias.Identification of new potential HIV-1 reverse transcriptase inhibitors by QSAR modeling and structure-based virtual screening.Uvaria angolensis as a promising source of inhibitors of HIV-1 RT-associated RNA-dependent DNA polymerase and RNase H functions.Can the ever-promising target HIV reverse transcriptase-associated RNase H become a success story for drug development?New Anthraquinone Derivatives as Inhibitors of the HIV-1 Reverse Transcriptase-Associated Ribonuclease H FunctionHuman Endogenous Retroviruses Are Ancient Acquired Elements Still Shaping Innate Immune Responses
P2860
Q26764925-18070AF2-51A3-4ED5-960E-D3FEADB45F84Q26777448-5FD7DF51-6912-4F12-9F98-A168584C0929Q28081195-9A3E6B26-FAB0-4DE9-829F-B7CD5E375C42Q28552768-2F9D3EE6-2CEB-4F39-9D2A-3A16328F2BF6Q30352778-70C675F2-B413-4ABB-958F-63E1D81B0E9CQ33649797-6A5B554D-B06F-4A7D-8498-9EE398E35769Q33798319-13938CFE-0696-4555-97B0-6C4B5DE61742Q34527699-37B97D7F-975B-4BF1-A1EB-41F562B20C5AQ35102778-37F93131-FE07-40FF-899E-8781FE3DE1ACQ35105821-36AB6081-A078-46E0-997F-35E3AB31D22BQ35237036-2E602376-535F-4AE9-B7AE-55443FFA99C7Q35288330-FFA5244A-C558-4A66-A81E-62A34A524148Q35650700-40F7BD8B-CCE2-4D11-994B-3F3947F20934Q35946765-530C457F-84C8-4E70-98FA-69C198E55D29Q35962212-D3780E20-CFE2-498D-8768-E51A2260EEAAQ36221687-9B75AD22-9CD8-498C-98F6-AA9EA1EBD803Q37045832-FD696A25-9C2E-49E7-BEE4-A738AEFA9F9FQ37710343-D7F7F483-4D01-4AA7-88F7-0E8E222999E7Q38212854-31D9EA6A-8AF7-41EE-A27C-BD226E341D33Q38968700-3C1E3D19-964D-4AF7-8B0B-88C1941CE3B9Q39443607-2B2486F5-54CE-42AB-AF2C-070C51524832Q39627553-A704FC59-CBD6-44CC-976D-BC2CD66DCE25Q40395197-51A4B9F6-108A-4594-87C4-C42825154A34Q40668088-2FB61BAF-A54B-49B3-893E-952745B69468Q40856431-78839284-63BF-4678-A2B5-42F2ACF94BC5Q40942917-4D54FF24-47EB-4713-8002-733BDEADAAF1Q41040182-317F0A38-DBF8-47C0-875E-E6F18E29E940Q42060865-EAE301A9-D6C6-4CE0-9EBD-7CCD98F0E9E8Q47279853-D1E8D741-CBB8-4DA7-8809-CA6EFAD0DFA2Q53270036-AE4037B7-8A29-47D3-B904-5C0E551219FBQ58196879-747A5D67-6154-49C0-86DC-6C652DEA9599Q58196901-98404C90-2401-4FCC-B595-2B28D09B67D7Q58754303-A930A4A8-938F-4C1E-8540-D6B6BDACA05B
P2860
HIV-1 Reverse Transcriptase Still Remains a New Drug Target: Structure, Function, Classical Inhibitors, and New Inhibitors with Innovative Mechanisms of Actions.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
HIV-1 Reverse Transcriptase St ...... ovative Mechanisms of Actions.
@en
type
label
HIV-1 Reverse Transcriptase St ...... ovative Mechanisms of Actions.
@en
prefLabel
HIV-1 Reverse Transcriptase St ...... ovative Mechanisms of Actions.
@en
P2860
P50
P356
P1476
HIV-1 Reverse Transcriptase St ...... novative Mechanisms of Actions
@en
P2860
P304
P356
10.1155/2012/586401
P577
2012-06-20T00:00:00Z